FDA Approves Recorlev for Adults With Endogenous Cushing’s

FDA Approves Recorlev for Adults With Endogenous Cushing’s

315523

FDA Approves Recorlev for Adults With Endogenous Cushing’s

The U.S. Food and Drug Administration (FDA) has approved Recorlev (levoketoconazole) to treat adults with endogenous Cushing’s syndrome for whom surgery is not an option or has not been effective. The therapy is expected to be available in the U.S. in the coming months. To ensure access to Recorlev, the company has created Xeris CareConnection, a program for patients and their caregivers, including one-on-one support, educational resources, and financial assistance. The program will also provide…

You must be logged in to read/download the full post.